Second-Line Afatinib versus Erlotinib for Patients with Squamous Cell Carcinoma of the Lung (LUX-Lung 8): Analysis of Tumor and Serum Biomarkers

Felip, EnriquetaSoria, Jean-CharlesCobo, ManuelLu, ShunSyrigos, KostasLee, Ki HyeongGoker, ErdemGeorgoulias, VassilisLi, WeiGuclu, SalihIsla, DoloresMin, Young JooMorabito, AlessandroArdizzoni, AndreaGadgeel, ShirishDupuis, NicholasGibson, NeilKraemer, NicoleBuehnemann, ClaudiaSolca, FlavioEhrnrooth, EvaGoss, Glenwood2019-10-272019-10-2720171556-08641556-1380https://hdl.handle.net/11454/32780eninfo:eu-repo/semantics/closedAccessSquamous cell carcinoma of the lungNSCLCafatinibSecond-Line Afatinib versus Erlotinib for Patients with Squamous Cell Carcinoma of the Lung (LUX-Lung 8): Analysis of Tumor and Serum BiomarkersConference Object121S1186S1187WOS:000413055802480Q1